About iO BiO Sciences

iO BiO Sciences developed a novel, proprietary, genetic cell modification technology (GEMS™), allowing efficient, plug-and-play, manufacturing of Advanced Therapy Medicinal Products and Biomolecule Manufacturing.

The GEMS™ technology is used to develop clinical off-the-shelf cell therapies in oncology using a universal NK cell derived from a proprietary pluripotent stem cell.

iO BiO Sciences technology is also applicable to biomanufacturing of proteins or viral vectors in stable mammalian cell lines converting producer cell lines into a plug-and-play manufacturing systems with only one variable: the gene of interest.

Our Mission

Enable the rapid development of cell therapies to fight cancer using off-the-shelf natural killer cells derived from a unique stem source and engineered for flexibility, efficacy, and mass production.

iO BiO is focused on developing Natural Killer Cell therapies to fight cancers, initially focused on liver cancer. Our multi-part system allows for flexible therapy development and license opportunities.

iO BiO
CAR-NK-based Cell Therapy

Immune Cell Therapies Engineered for Efficacy and Mass Production

Allogeneic

Facilitates efficient off-the-shelf product model

Precision

IP Suite that refines and improves gene editing

Flexible

Product build readily scalable to multiple new targets

Virus Free

Uses electroporation, saving time and reducing cost

Our Leadership

Sicco H Popma, PhD

CEO, Founder

CEO & President iO Biosciences, Inc
25+ Years Research & Development Experience
13 Years Johnson & Johnson
15+ Years Cell Therapy Development
PhD, Immunology, Univ. Groningen, The Netherlands
Scientist. U. Pennsylvania, USA

Yuta Lee

Director, Founder

President ZMI Electronics
10+ Years Cell Therapy Development, Accelerated Biosciences.
EMBA CEIBS, Shanghai, China
BA UC Berkeley, Economy & Law, USA

Martina Molsbergen

Business Development

CEO C14 Consulting
25+ Years business development, marketing and entrepreneurial experience in biotherapeutics, immunotherapies and regenerative medicine.
BS, Chemistry Drexel University

iO BiO Sciences Investors

Contact Sicco Popma for investment opportunities